Predicting immuno-oncology therapies efficacy or related toxicities with pre-clinical models is still a challenge.
The mechanisms of actions involved in human immune responses against cancer cells include boosting the immune system via innate cells activation, increased phagocytosis, stimulation of antigen presenting cells, enhanced cytotoxic cells activity or dampening the immunosuppressive environment of the tumor.
To date, many mouse pre-clinical models are available to assess the efficacy of cell therapies (TILs, engineered T cells, CAR-T cells, NK cells), bi-specific antibodies, cancer vaccines or checkpoint modulators.
We recently partnered with Xtalks for the webinar, "Humanized Mouse Models be Used to Study Cancer & the Development of New Immune-Targeted Therapies?" In this webinar you will learn about:
At TransCure bioServices, we have developed tumor models which recapitulate both the human tumor micro-environment and human immune responses. Mice are humanized using hematopoietic stem cells (HSC CD34+) isolated from human cord blood. Human tumor cell line-derived xenografts (CDX) are then engrafted in these humanized mouse models to assess in vivo the efficacy and/or toxicity of immune-oncology therapies and the disease progression.
By contrast to syngeneic mouse models, this model provides a way to test your final drug product in a human tumor micro-environment, with no need of a mouse surrogate.
Fill out the form to gain immediate access to this presentation.